JTK 853

Drug Profile

JTK 853

Alternative Names: JTK-853

Latest Information Update: 01 May 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Japan Tobacco
  • Developer Akros Pharma; Japan Tobacco
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 26 Apr 2012 Discontinued - Phase-I for Hepatitis C in Puerto Rico (PO)
  • 26 Apr 2012 Discontinued - Phase-I for Hepatitis C in USA (PO)
  • 30 Sep 2011 Japan Tobacco completes a phase I trial in Hepatitis C in Puerto Rico (NCT01473056)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top